tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Heron Therapeutics sees FY24 revenue $138M-$158M, consensus $156.57M

Sees FY24 oncology care franchise up 3%-5% over 2023, and the acute care franchise up in excess of 48% year-over-year. Sees FY24 operating $108M-$116M; EBITDA ($22M)-$3M.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on HRTX:

Disclaimer & DisclosureReport an Issue

1